Windlas Biotech is a pharmaceutical contract development and manufacturing partner that does something unusual for its industry - it owns the intellectual property on almost everything it makes for its customers, not just the factory space. Founded in 2001 in Dehradun by the Windlass family and now one of India’s top five domestic generic formulations CDMOs, the company spent 25 years building a model where it develops a drug, secures the regulatory approvals, and then manufactures it for pharma companies who sell it under their own brand names. That IP-owning approach - combined with a set of fungible factories that can pivot between contract manufacturing, the company’s own trade generics brand, and exports - is the recurring logic that explains everything else. # Business segments Three engines fed by the same five factories - a contract manufacturing core that owns the science, a trade generics arm that reaches India’s villages without a sales force, and a small but fast-growing exports business targeting markets where local production is scarce. ## 1. Generic Formulations CDMO: the partner that owns the recipe **Windlas is not a job-worker selling machine time - it develops, licenses and manufactures generic drugs for India’s largest pharma companies, and it owns the intellectual property on 99% of the products it supplies.** - **IP owner, not just a factory** - the company holds the entire intellectual property from formulation development through regulatory permission for nearly 100% of its CDMO supplies, which means customers are buying a ready-made, approved product rather than renting capacity. - **Cost-plus contracts with sticky customers** - revenue comes from development fees and manufacturing charges on a cost-plus basis, insulating profitability from raw-material price swings, while relationships are long-standing and exclusive enough that the company plans capital expenditure around them. - **Quality as a sales pitch** - the four main plants undergo 70 to 80 customer audits a year, and permanent quality representatives from customers are stationed inside the facilities, which is how the company turns regulatory rigour into a competitive advantage. ## 2. Trade Generics & Institutional: the brand that skips the sales rep **The company markets its own generic drugs directly to stockists and government hospitals, targeting the 70% of India that lives in villages and small towns - no medical representatives, just channel substitution.** - **Bypasses the doctor-detailing model** - branded generics are typically promoted to physicians by sales representatives; Windlas sells its 546 own-brand products through stockists and distributors, saving the cost of a field force and passing affordability to the buyer. - **Built for semi-urban and rural India** - the portfolio is aimed at the more than 650,000 villages and small kasbas where most Indians live, with products in respiratory, anti-diabetic and gastroenterology therapies priced for those markets. - **Policy tailwinds are structural** - government schemes like Ayushman Bharat and Jan Aushadhi Yojana, plus a target to more than double Jan Aushadhi stores to 25,000, are expanding the generic-acceptance habit that this vertical feeds on. ## 3. Exports: the regulatory passport play **A small but 40%-growing business that takes products developed and approved in India into emerging markets, using WHO-GMP certification as the entry ticket.** - **Dossier-first, revenue-later** - the company develops and registers product dossiers to secure marketing authorisations in target countries, a process with long lead times that then unlocks sales to local pharma companies and pharmacies. - **Emerging markets where production is scarce** - 67 products are exported across roughly 10 countries including Cambodia, Philippines, Sri Lanka and South Africa, with a focus on injectables where local manufacturing is limited. # Manufacturing backbone **Five fungible plants in Dehradun - soon to be six - that can switch output between CDMO, trade generics and exports as demand shifts, with quality systems that make the factories a customer-audit destination.** - **One campus, interchangeable lines** - all facilities are in Dehradun and serve all three business verticals interchangeably, so fixed costs are shared and capacity can be reallocated without building separate plants for each business. - **Capacity still has headroom** - total installed capacity of 8.5 billion tablets and capsules ran at 66% utilisation in FY26, up from 43% three years earlier, meaning growth does not yet require a step-change in capital spending. - **Injectables are the new margin lever** - Plant-5, commissioned in March 2024, makes ampoules, liquid vials and lyophilized vials for critical care, with higher gross margins than oral solids but also higher fixed operating costs from round-the-clock air handling and microbial control. - **Audited into trust** - 250 quality control personnel, an electronic quality management system across all plants, and 70 to 80 customer audits a year create a compliance record that is itself a selling point in an industry facing tightening Schedule M and global regulatory scrutiny. # Group structure and partners **A single listed company with no active subsidiaries - the three business verticals are internal units, not separate legal entities, and the promoter family runs the operations directly.** - **One entity, one set of books** - standalone and consolidated financials are identical, confirming no active subsidiaries; a legacy US subsidiary is being dissolved. - **Promoter-led with professional management** - Hitesh Windlass is Managing Director, Manoj Kumar Windlass is Joint Managing Director, and Komal Gupta serves as both CEO and CFO, combining family ownership with executive continuity. - **First CDMO to list** - the company went public on NSE and BSE in August 2021, the first Indian pharmaceutical CDMO to do so, and has since completed a ₹25 crore share buyback from public shareholders.